Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation (NYSE: SYK) is described as a global leader in medical technologies, with a focus on MedSurg, Neurotechnology and Orthopaedics. The news flow around Stryker reflects this broad footprint, covering topics from product launches and clinical technology updates to quarterly financial results, leadership changes and portfolio transactions.
Investors following SYK news will see regular announcements of earnings results, including detailed third quarter and other period operating updates furnished via press releases and Form 8-K filings. These communications typically discuss segment performance in MedSurg and Neurotechnology and Orthopaedics, along with commentary from management on sales trends and margins.
Stryker also issues news about product innovation in orthopaedics and trauma. Recent examples include the launch of the FDA-cleared Incompass Total Ankle System for patients with end-stage ankle arthritis and updates on trauma offerings such as the Pangea platform and T2 Alpha system, which are designed to support complex fracture management. These announcements often coincide with major medical society meetings and highlight design goals and clinical use cases.
Corporate and strategic developments appear frequently in Stryker’s news stream. The company has reported leadership changes, such as the appointment of a President and Chief Operating Officer and the promotion of a new Group President, Orthopaedics. It has also communicated portfolio moves, including references to the divestiture of its spinal implant business and news that VB Spine LLC acquired Stryker’s U.S. spine implant business and a spine implant manufacturing facility in Cestas, France.
In addition, Stryker announces investor events, such as upcoming earnings webcasts, participation in healthcare conferences and Investor Day presentations. For investors and healthcare professionals, the SYK news page provides a centralized view of these financial, strategic and product-related updates, offering context on how the company’s medical technologies and corporate decisions evolve over time.
Stryker (NYSE:SYK) has announced its quarterly dividend declaration of $0.84 per share. The dividend will be payable on July 31, 2025, to shareholders of record as of June 30, 2025. This dividend amount represents a 5.0% increase compared to the previous year while remaining unchanged from the last quarter's distribution.
Stryker (NYSE:SYK) has announced its participation in the upcoming Bank of America Securities 2025 Global Healthcare Conference. The event will take place on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada.
Key details:
- Presenters: Preston Wells (Vice President and Chief Financial Officer) and Jason Beach (Vice President, Finance and Investor Relations)
- Presentation Time: 1:40 p.m. Pacific Time
- Access: Live webcast and replay available on www.stryker.com
- Availability: Recording will be archived on the Investor Relations page
Stryker (NYSE:SYK) has scheduled its first quarter fiscal year 2025 financial results announcement for Thursday, May 1, 2025. The company will release a press release containing summary financial information at approximately 4:05 p.m. ET, covering the quarter ending March 31, 2025.
A webcast to discuss the Q1 2025 results will be held at 4:30 p.m. ET on the same day. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available on the company's website two hours after the live call concludes.
Stryker (NYSE: SYK) has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, , which will operate under the newly formed VB Spine, . The strategic divestment aims to enhance Stryker's focus and enable investments in areas with greater innovation and growth potential.
As part of the agreement, VB Spine will have exclusive access to Mako Spine and Copilot technologies for spine procedures. Stryker maintains its presence in the spine sector through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses, along with a strategic partnership with VB Spine.
The transaction's international component will be executed in phases, with transfers to VB Spine in certain markets pending legal, regulatory, and employee consultation requirements.
Stryker (NYSE:SYK) has nominated Emmanuel "Manny" Maceda to its board of directors, with the election scheduled for the Annual Meeting of Shareholders on May 8, 2025. Maceda brings over 30 years of experience in leading organizations and advising executives on corporate transformations.
Maceda currently serves as Chairman of Bain & Company, following his role as Worldwide Managing Partner and CEO from 2018 to 2024. During his leadership, he drove Bain's global transformation across 50+ offices, strengthening digital capabilities and expanding sustainability focus. Since joining Bain in 1989, he has held various senior leadership positions and advised CEOs on strategy, growth, and organizational effectiveness.
Stryker (NYSE:SYK) has scheduled its 2025 Annual Meeting of Shareholders for Thursday, May 8, 2025, at 9:30 a.m. Eastern Time. The meeting will be conducted virtually via the internet.
Shareholders can access the webcast, including audio and slide presentation, through the company's Investor Relations page at www.investorevents.stryker.com. For audio-only participation, attendees can dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Annual Meeting."
A recording will be available from 10:30 a.m. ET on May 9, 2025, at www.virtualshareholdermeeting.com/SYK2025 until the 2026 proxy statement filing.
Stryker (NYSE: SYK) unveiled significant advancements in its Mako SmartRobotics™ technology at AAOS 2025 Annual Meeting in San Diego. The company highlighted that Mako has achieved over 1.5 million procedures globally across 45 countries.
Key announcements include:
- Introduction of Mako Total Hip with Advanced Primary and Revision, featuring first-to-market robotic hip revision capability
- Launch of fourth-generation Mako 4 system, offering multiple applications across Total Hip, Total Knee, Partial Knee and Spine procedures
- Integration of fourth-generation Q Guidance System
- Expansion into Mako Spine and Mako Shoulder applications
The company completed initial Mako Spine cases in October and plans full U.S. commercial launch in second half of 2025. Mako Shoulder, introduced late last year, remains in market release through 2025.
Inari Medical, now part of Stryker (NYSE: SYK), has launched the Artix™ Thrombectomy System, a new medical device designed for peripheral arterial thrombectomy. The system combines aspiration and mechanical thrombectomy capabilities to address arterial blood clots in the legs, which are life- and limb-threatening emergencies.
The Artix system features a dual mechanical thrombectomy and aspiration toolkit, capable of removing acute to chronic clots in a single session. It includes an 8 Fr. low-profile sheath available in 65cm and 90cm lengths, and an innovative over-the-wire mechanical element. The system also incorporates a covered nitinol mesh funnel to minimize clot migration risk.
The first commercial case using Artix was performed by Dr. Jonathan Bowman at Norwalk Hospital on October 19, 2024. The device aims to overcome limitations of existing therapies, which can lead to ineffective clot retrieval, significant blood loss, vessel trauma, and high rates of lytic use.
Stryker (NYSE:SYK) has launched its latest personal protective equipment, the Steri-Shield 8 personal protection system. The new system features a customizable helmet with three points of contact and three toga choices, representing an evolution in healthcare PPE technology.
Key improvements include a helmet with three points of securement, a ponytail accommodation path, enhanced visibility with a brighter light and 22% wider field of vision compared to previous versions. The system also features a redesigned fan targeting the front and back of users' necks, a sleeker battery, and a more efficient charging station.
The three toga styles offer AAMI level 4 (2012) protection in all critical zones, providing maximum fluid and microbial barrier protection for healthcare professionals.